1. Indium-111In-Pentetreotide prolongs survival in gastroenteropancreatic malignancies;Anthony;Semin Nucl Med,2002
2. Patient specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship;Barone;J Nucl Med,2005
3. Biology and imaging of neuro-endocrine tumors;Baudin;Rev Prat,2002
4. Long term efficacy of high-activity 111In-Pentreteotide therapy in patients with disseminated neuroendocrine tumors;Buscombe;J Nucl Med,2003
5. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study;Bodei;Eur J Nucl Med Mol Imaging,2003